America Great Health (AAGH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
America Great Health (AAGH) trades at $0.00 with AI Score 56/100 (Grade B). America Great Health (AAGH) is a U. S. -based biotechnology company focused on the research and development of protein and peptide small molecular drugs. Market cap: $2.12M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for AAGH: AAGH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AAGH against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AAGH: 3/6 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →America Great Health (AAGH) Healthcare & Pipeline Overview
America Great Health (AAGH) is a U.S.-based biotechnology company specializing in the research and development of protein and peptide small molecular drugs. It also manufactures and sells AI cloud computing-based diagnostic and medical devices, alongside developing cell therapy, regenerative medicine, and health supplements, operating within the dynamic healthcare sector.
What Is the Investment Thesis for AAGH?
America Great Health (AAGH) operates as a biotechnology firm with a diverse focus spanning protein/peptide drug R&D, AI-driven diagnostics, cell therapy, regenerative medicine, and supplements. The company's reported gross margin of 73.5% indicates strong potential profitability on its product sales, despite a current profit margin of -150.6%, which is typical for early-stage biotech companies heavily investing in R&D. Its strategic emphasis on AI cloud computing-based diagnostic devices and advanced cell therapies positions it within high-growth segments of the healthcare market. While the company's beta of 6.35 suggests significant volatility, reflecting its small market capitalization and OTC listing, this also implies potential for substantial price movements based on R&D breakthroughs or market adoption. Key value drivers include successful progression of its drug pipeline, commercialization of AI diagnostic tools, and expansion within the regenerative medicine and supplement markets. The company's ability to transition from R&D investment to revenue generation and achieve positive profit margins will be critical for long-term value creation.
Based on FMP financials and quantitative analysis
AAGH Key Highlights
- Market capitalization is currently reported as $0.00 billion, indicating a very small market valuation.
- The company maintains a strong gross margin of 73.5%, suggesting efficient cost management relative to revenue from goods sold.
- A significant negative profit margin of -150.6% reflects substantial operating losses, likely due to intensive R&D investments.
- America Great Health exhibits a high beta of 6.35, indicating considerably higher volatility compared to the broader market.
- The company does not currently pay a dividend, consistent with its early-stage biotechnology focus and negative profitability.
Who Are AAGH's Competitors?
AAGH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AAGH's Key Strengths?
- Diverse portfolio spanning drug R&D, AI diagnostics, cell therapy, and supplements.
- High gross margin of 73.5% on current operations.
- Strategic focus on high-growth areas within biotechnology and healthcare.
- Headquartered in Alhambra, California, a hub for biotech innovation.
What Are AAGH's Weaknesses?
- Significant negative profit margin of -150.6%, indicating substantial operating losses.
- Very small employee base of 5, potentially limiting R&D and commercialization scale.
- OTC Other tier listing, typically associated with lower liquidity and less stringent disclosure.
- Unknown disclosure status, which can deter institutional investors.
What Could Drive AAGH Stock Higher?
- **Upcoming**: Potential regulatory milestones for protein/peptide drug candidates or AI diagnostic devices.
- **Upcoming**: Successful completion of initial clinical trials for cell therapy or regenerative medicine programs.
- **Ongoing**: Expansion of the sales and distribution network for AI cloud computing-based diagnostic and medical devices.
- **Ongoing**: Introduction of new health supplement products to diversify revenue streams.
- **Upcoming**: Formation of strategic partnerships or collaborations to accelerate R&D or market access.
What Are the Key Risks for AAGH?
- **Ongoing**: Significant negative profit margin of -150.6% indicates ongoing operational losses.
- **Potential**: High beta of 6.35 suggests extreme stock price volatility, potentially leading to substantial capital loss.
- **Ongoing**: Dependence on successful, lengthy, and costly research and development for future drug and therapy commercialization.
- **Potential**: Intense competition from larger, better-funded companies in all its operating segments.
- **Ongoing**: Risks associated with its OTC Other listing, including limited liquidity, unknown disclosure, and potential for market manipulation.
What Are the Growth Opportunities for AAGH?
- **Advancement in Protein and Peptide Small Molecular Drugs:** America Great Health's dedicated research and development in protein and peptide small molecular drugs represents a significant growth avenue. The global peptide therapeutics market was valued at approximately $40 billion in 2023 and is projected to grow substantially, driven by their high specificity, potency, and lower toxicity compared to traditional small molecules. AAGH's ability to successfully identify, develop, and bring to market novel drug candidates in this area could unlock considerable revenue streams. The timeline for drug development is typically long, spanning 10-15 years from discovery to market, but successful early-stage clinical trial results could serve as significant catalysts, attracting partnerships and funding.
- **Expansion of AI Cloud Computing-Based Diagnostic Devices:** The market for AI in healthcare diagnostics is experiencing exponential growth, projected to reach over $50 billion by 2030, driven by demand for improved accuracy, efficiency, and personalized medicine. AAGH's manufacturing and sale of AI cloud computing-based diagnostic and medical devices positions it to capitalize on this trend. Developing proprietary algorithms and robust cloud infrastructure could provide a competitive edge. Growth here would involve securing regulatory approvals, establishing distribution channels, and demonstrating clinical utility, potentially within the next 3-5 years as healthcare systems increasingly adopt AI solutions.
- **Development and Commercialization of Cell Therapy:** Cell therapy is a revolutionary field with a global market size expected to exceed $20 billion by 2028, fueled by breakthroughs in gene editing and stem cell research. AAGH's involvement in cell therapy offers a high-potential, albeit high-risk, growth opportunity. Successful development of novel cell-based treatments for specific diseases could lead to significant market penetration. The timeline for clinical development and regulatory approval for cell therapies is rigorous, often taking 5-10 years, but successful clinical milestones could attract substantial investment and partnerships, validating its therapeutic approaches.
- **Penetration into Regenerative Medicine Markets:** Regenerative medicine, closely related to cell therapy, focuses on replacing or regenerating human cells, tissues, or organs to restore normal function. This market is projected to reach over $150 billion by 2030, driven by an an aging global population and increasing prevalence of chronic diseases. AAGH's activities in this area could involve developing tissue engineering products, biomaterials, or gene therapies. Strategic partnerships with academic institutions or larger pharmaceutical companies could accelerate its progress. Commercialization efforts could materialize within a 5-7 year timeframe, contingent on regulatory success and clinical efficacy.
- **Growth in the Health and Wellness Supplement Market:** While more established, the global dietary supplements market is robust, valued at over $170 billion and projected to grow steadily. AAGH's manufacturing and sale of supplements provides a more immediate revenue stream compared to its long-term R&D projects. Expanding its product line with scientifically backed formulations, enhancing marketing and distribution, and potentially targeting specific health concerns could drive consistent growth. This segment offers a shorter commercialization cycle, with market expansion opportunities potentially realized within 1-3 years through effective branding and consumer outreach.
What Opportunities Does AAGH Have?
- Growing global demand for advanced diagnostic tools, cell therapies, and regenerative medicine.
- Potential for breakthroughs in protein and peptide drug development.
- Expansion of its health supplement product lines and distribution.
- Strategic partnerships or acquisitions to accelerate R&D and market reach.
What Threats Does AAGH Face?
- Intense competition from larger, well-funded pharmaceutical and biotech companies.
- High regulatory hurdles and lengthy approval processes for drugs and advanced therapies.
- Reliance on successful R&D, which carries inherent risks of failure and significant costs.
- Market volatility and limited investor interest due to OTC listing and small market capitalization.
What Are AAGH's Competitive Advantages?
- Specialized R&D focus on protein and peptide small molecular drugs, a complex area requiring significant scientific expertise.
- Integration of AI cloud computing into diagnostic and medical devices, offering potential for enhanced accuracy and efficiency.
- Early-stage positioning in emerging fields like cell therapy and regenerative medicine, which have high barriers to entry.
- Proprietary intellectual property developed through its research efforts, though specific patents are not detailed.
What Does AAGH Do?
America Great Health, operating under the ticker AAGH, is a biotechnology company based in the United States, headquartered in Alhambra, California. Founded in 2013, the company initially operated as Crown Marketing before undergoing a significant transformation and rebranding to America Great Health in March 2017, signaling a strategic pivot towards the burgeoning healthcare and biotechnology sectors. The company's core activities are multifaceted, encompassing both pioneering research and development alongside the manufacturing and sale of advanced medical products. A primary focus lies in the intricate field of protein and peptide small molecular drugs, where its research endeavors aim to uncover novel therapeutic solutions. Beyond drug discovery, America Great Health is actively involved in the development and commercialization of AI cloud computing-based diagnostic and medical devices. This segment leverages artificial intelligence to enhance the precision and efficiency of medical diagnostics, a critical area in modern healthcare. Furthermore, the company has established a presence in the cutting-edge domains of cell therapy and regenerative medicine, areas that hold immense promise for treating a wide array of conditions by repairing or replacing damaged tissues and cells. Complementing these advanced medical pursuits, America Great Health also manufactures and sells health supplements, broadening its product portfolio to address general wellness and preventative health needs. With a lean operational structure, employing 5 individuals, AAGH navigates the complex biotechnology landscape, aiming to innovate across several high-potential healthcare niches. Its strategic location in California positions it within a vibrant hub for biotech research and development, though its current operational scale and OTC listing suggest a focus on niche market penetration and foundational R&D efforts.
What Products and Services Does AAGH Offer?
- Conducts research and development of protein and peptide small molecular drugs.
- Manufactures and sells AI cloud computing-based diagnostic devices.
- Manufactures and sells AI cloud computing-based medical devices.
- Engages in the development of cell therapy treatments.
- Focuses on advancements in regenerative medicine.
- Produces and distributes health supplements.
- Operates as a biotechnology company in the United States.
How Does AAGH Make Money?
- Generates revenue through the manufacturing and sale of AI cloud computing-based diagnostic and medical devices.
- Derives income from the manufacturing and sale of health supplements.
- Aims for future revenue generation from the successful development and commercialization of protein and peptide small molecular drugs, cell therapies, and regenerative medicine products.
- Potentially seeks partnerships or licensing agreements for its R&D pipeline.
What Industry Does AAGH Operate In?
America Great Health operates within the dynamic and innovation-driven Biotechnology industry, a sub-sector of the broader Healthcare sector. This industry is characterized by intensive research and development, aiming to create novel drugs, therapies, and diagnostic tools. AAGH's focus on protein and peptide small molecular drugs places it in a competitive field, where advancements in molecular biology and drug delivery are paramount. The company's foray into AI cloud computing-based diagnostic and medical devices aligns with a significant trend in healthcare towards digitalization and precision medicine, where artificial intelligence is increasingly used to improve diagnostic accuracy and treatment efficacy. Furthermore, its involvement in cell therapy and regenerative medicine positions it in areas experiencing rapid scientific progress and growing market interest, driven by the potential to address previously untreatable conditions. While the overall biotechnology market is vast and growing, AAGH, with its small employee base and OTC listing, likely targets niche segments, competing with both established pharmaceutical giants and numerous smaller, specialized biotech startups.
Who Are AAGH's Key Customers?
- Healthcare providers and hospitals for diagnostic and medical devices.
- Patients seeking advanced cell and regenerative therapies (upon commercialization).
- Consumers purchasing health supplements directly or through retail channels.
- Research institutions and pharmaceutical companies for potential R&D collaborations.
How America Great Health Is Valued
America Great Health carries a market capitalization of $2.12M, placing it in the micro-cap category. Relative to its peer group, AAGH's quantitative score of 56/100 is below the peer average of 76/100.
Company Profile
America Great Health operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Alhambra, US. The company is led by CEO Mike Qingkun Wang. AAGH has traded publicly since 2012.
ROE 10%Key Financial Metrics
Return on equity for America Great Health stands at 10.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -11.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -27.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
America Great Health's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
AAGH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diverse portfolio spanning drug R&D, AI diagnostics, cell therapy, and supplements.
- High gross margin of 73.5% on current operations.
- Strategic focus on high-growth areas within biotechnology and healthcare.
- Headquartered in Alhambra, California, a hub for biotech innovation.
Bear Case
- Significant negative profit margin of -150.6%, indicating substantial operating losses.
- Very small employee base of 5, potentially limiting R&D and commercialization scale.
- OTC Other tier listing, typically associated with lower liquidity and less stringent disclosure.
- Unknown disclosure status, which can deter institutional investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
AAGH Latest News
No recent news available for AAGH.
AAGH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AAGH.
Price Targets
Wall Street price target analysis for AAGH.
AAGH MoonshotScore
What does this score mean?
The MoonshotScore rates AAGH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mike Qingkun Wang
Chief Executive Officer
Mike Qingkun Wang serves as the Chief Executive Officer of America Great Health, leading the company's strategic direction and operations. While specific details regarding his educational background and prior career history before joining AAGH are not provided in the available data, his role involves managing the company's team of 5 employees. His leadership is central to guiding America Great Health's diverse pursuits in biotechnology, including the research and development of protein and peptide small molecular drugs, as well as the manufacturing and sale of AI cloud computing-based diagnostic devices and cell therapy solutions.
Track Record: Under Mike Qingkun Wang's leadership, America Great Health has maintained its focus on advanced biotechnology and healthcare solutions since its rebranding in March 2017. He oversees the company's efforts in developing innovative products across multiple segments, from drug discovery to AI diagnostics and regenerative medicine. His tenure is marked by the company's continued operation in these specialized fields, aiming to navigate the complex landscape of biotech R&D and commercialization with a lean operational structure.
AAGH OTC Market Information
America Great Health trades on the "OTC Other" tier, which is the lowest of the three OTC Markets tiers (OTC Pink, OTCQB, OTCQX). Companies on OTC Other are not required to meet minimum financial standards or provide regular disclosures to OTC Markets Group, unlike those on OTCQB or OTCQX, or major exchanges like NYSE or NASDAQ. This tier is typically for companies that are unwilling or unable to provide disclosure to the public markets, often due to their size, early stage, or financial condition. It signifies a significant difference in regulatory oversight and transparency compared to exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and wide bid-ask spreads, making trading difficult and potentially costly.
- Lack of consistent public disclosure, hindering informed investment decisions.
- Higher volatility compared to exchange-listed stocks due to lower trading volumes and less oversight.
- Potential for manipulation due to less regulatory scrutiny and limited transparency.
- Difficulty in obtaining financing or attracting institutional investment due to perceived higher risk.
- Verify any available financial statements directly from the company or state corporate registries.
- Research management's background and track record beyond what is publicly stated.
- Understand the company's specific product development timelines and regulatory pathways.
- Assess the competitive landscape and market size for each of AAGH's diverse product areas.
- Investigate any news or press releases for signs of operational activity or partnerships.
- Examine any legal or regulatory filings that might be available through other channels.
- Evaluate the company's capital structure and potential need for future financing.
- Clearly defined business operations in biotechnology, including R&D and product manufacturing.
- Established founding year (2013) and a history of operations, including a name change.
- Specific headquarters location in Alhambra, California.
- Identified CEO, Mike Qingkun Wang, leading the company.
- Focus on high-potential, albeit complex, areas like AI diagnostics and cell therapy.
America Great Health Healthcare Stock: Key Questions Answered
What does America Great Health do?
America Great Health (AAGH) is a U.S.-based biotechnology company with a diversified operational focus. Its core activities include the research and development of protein and peptide small molecular drugs, aiming to discover and bring to market novel therapeutic compounds. Additionally, the company is involved in the manufacturing and sale of AI cloud computing-based diagnostic and medical devices, leveraging artificial intelligence to enhance healthcare diagnostics. AAGH also explores advanced medical fields such as cell therapy and regenerative medicine, which hold promise for treating various diseases by repairing or replacing damaged tissues. Complementing these high-tech ventures, the company manufactures and sells health supplements, catering to general wellness.
How does America Great Health manage the risks associated with its R&D pipeline?
America Great Health operates in the biotechnology sector, where R&D pipelines inherently carry significant risks, including high costs, lengthy development timelines, and potential for clinical trial failures. While specific risk management strategies for AAGH's pipeline are not detailed in the provided information, typical approaches in this industry include diversifying the pipeline across multiple therapeutic areas (as AAGH does with protein/peptide drugs, cell therapy, and regenerative medicine) to mitigate the impact of any single project's failure. Furthermore, a high gross margin of 73.5% suggests that successful products could be highly profitable, potentially offsetting R&D expenses over time.
What are the implications of America Great Health's OTC Other listing for investors?
America Great Health's listing on the OTC Other tier carries several important implications for investors. Primarily, this tier has the least stringent disclosure requirements, and AAGH's disclosure status is "Unknown," meaning there is limited public financial and operational information available. This lack of transparency makes comprehensive due diligence challenging. Furthermore, OTC Other stocks typically experience very low trading volumes, leading to limited liquidity. Investors may face difficulties buying or selling shares quickly, and wide bid-ask spreads can result in unfavorable transaction prices. The stock's high beta of 6.35 also indicates extreme volatility, which, combined with low liquidity, can lead to significant price fluctuations and increased investment risk.
What are the key factors to evaluate for AAGH?
America Great Health (AAGH) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does AAGH data refresh on this page?
AAGH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AAGH's recent stock price performance?
America Great Health (AAGH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse portfolio spanning drug R&D, AI diagnostics, cell therapy, and supplements. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AAGH overvalued or undervalued right now?
Valuing America Great Health (AAGH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AAGH?
Before investing in America Great Health (AAGH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is strictly based on provided source data; no external research was conducted.
- Specific details regarding CEO background and track record are limited to the provided information.